D. Boral Capital Facilitates $15 Million Private Placement for Plus Therapeutics

Plus Therapeutics, Inc. (Nasdaq:PSTV), a clinical-stage pharmaceutical company, announced a private placement expected to raise approximately $15 million. The funds aim to advance the development of targeted radiotherapeutics for central nervous system cancers. D. Boral Capital acted as the exclusive placement agent for this transaction.

The offering includes 28,042,140 common units featuring shares of common stock and Series A and B warrants, with an initial exercise price of $1.32 and $1.98, respectively. The transaction's completion is contingent upon customary conditions and confirmation from Nasdaq, preventing potential delisting.

Net proceeds will address outstanding promissory notes and support general corporate needs. The securities are offered in a private placement, targeting accredited investors only, and are not registered under the Securities Act of 1933.